Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia

Monotherapy with Tadalafil or Tamsulosin Similarly Improved Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in an International, Randomised, Parallel, Placebo-Controlled Clinical Trial

(2012) Matthias Oelke et al.   EUROPEAN UROLOGY

Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms

(2011) M. İ. Öztürk et al.   ANDROLOGIA

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study

(2011) Craig F. Donatucci et al.   BJU INTERNATIONAL

Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial

(2011) Hartmut Porst et al.   EUROPEAN UROLOGY

Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo‐Controlled, Double‐Blind Study

(2011) Russell Blair Egerdie et al.   Journal of Sexual Medicine

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action

(2011) Karl-Erik Andersson et al.   NEUROUROLOGY AND URODYNAMICS

Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction

(2010) Stefan Ückert et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Lack of Pharmacodynamic Interaction of Silodosin, a Highly Selective α1a-Adrenoceptor Antagonist, With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men

(2010) Scott A. MacDiarmid et al.   UROLOGY

Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

(2009) Thierry Roumeguère et al.   BJU INTERNATIONAL

Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS

(2009) Karin S. Coyne et al.   BJU INTERNATIONAL

Characterization of Phosphodiesterase Type 5 Expression and Functional Activity in the Human Male Lower Urinary Tract

(2009) Benedetta Fibbi et al.   Journal of Sexual Medicine

Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies

(2009) Leonard S. Marks et al.   JOURNAL OF UROLOGY

Watchful waiting in benign prostatic hyperplasia

(2008) Jeremy Wiygul et al.   CURRENT OPINION IN UROLOGY

A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

(2008) Christian G. Stief et al.   EUROPEAN UROLOGY

The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors

(2008) Tobias S. Köhler et al.   EUROPEAN UROLOGY

Comparative Efficacy Assessment of Tamsulosin vs. Tamsulosin Plus Tadalafil in the Treatment of LUTS/BPH. Pilot Study

(2008) Amado Bechara et al.   Journal of Sexual Medicine

Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study

(2008) Claus G. Roehrborn et al.   JOURNAL OF UROLOGY

Effects of Phosphodiesterase Inhibitors on Tension Induced by Norepinephrine and Accumulation of Cyclic Nucleotides in Isolated Human Prostatic Tissue

(2008) Stefan Ückert et al.   UROLOGY

The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study

(2007) Claus G. Roehrborn et al.   JOURNAL OF UROLOGY